Translational medication development for nicotine addiction

American Journal of Health Behavior

Volumn 34, Issue 3, 2010, Pages 267-274

  Morgan, Glen ^a   Backinger, Cathy ^a   Lerman, Caryn ^b   Vocci, Francis ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c FRIENDS RESEARCH INSTITUTE   (United States)

Author keywords

Addiction; Medication development; Nicotine; Tobacco

Indexed keywords

CONFERENCE PAPER; DRUG DEVELOPMENT; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; TOBACCO DEPENDENCE; TRANSLATIONAL RESEARCH;

DRUG DISCOVERY; EVIDENCE-BASED MEDICINE; HUMANS; TOBACCO USE DISORDER; TRANSLATIONAL RESEARCH;

EID: 77449153753     PISSN: 10873244     EISSN: None     Source Type: Journal    
DOI: 10.5993/AJHB.34.3.2     Document Type: Review

References (42)

1. Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs. 2006;11:429-444. (Pubitemid 44386368)
2. Shiffman S, Scharf DM, Shadel WG, et al. Analyzing milestones in smoking cessation: Illustration in a nicotine patch trial in adult smokers. J Consult Clin Psych. 2006;74:276-285. (Pubitemid 43807360)
3. Wileyto EP, Patterson F, Niaura R, et al. Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine Tob Res. 2005;7:257-268. (Pubitemid 40852153)
4. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985-994. (Pubitemid 46227486)
5. Moolchan ET, Fagan P, Fernander AF, et al. Addressing tobacco-related health disparities. Addiction (Abingdon, England). 2007;102(Suppl 2):30-42. (Pubitemid 47390244)
6. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: A populationbased prevalence study. JAMA. 2000;284:2606-2610.
7. George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiat. 2008;63(11):1092-1096.
8. Gray NJ, Henningfield JE. A long-term view of harm reduction. Nicotine Tob Res. 2004;6:759-764. (Pubitemid 39504449)
9. Hatsukami DK, Slade J, Benowitz NL, et al. Reducing tobacco harm: Research challenges and issues. Nicotine Tob Res. 2002;4(Suppl 2):S89-S101. (Pubitemid 36104366)
10. Gray N, Henningfield JE, Benowitz NL, et al. Toward a comprehensive long term nicotine policy. Tob Control. 2005(14):161-165. (Pubitemid 40814066)
11. Royal College of Physicians. Harm reduction in nicotine addiction: Helping people who can't quit. A Report by the Tobacco Advisory Group of the Royal College of Physicians. London: RCP, 2007.
12. Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov. 2007;6:746-762. (Pubitemid 47338182)
13. Walters CL, Cleck JN, Kuo YC, et al. Muopioid receptor and CREB activation are required for nicotine reward. Neuron. 2005;46:933-943. (Pubitemid 40805353)
14. O'Malley SS, Cooney JL, Krishnan-Sarin S, et al. A controlled trial of naltreone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med. 2006;166:667-664.
15. David S, Lancaster T, Stead LF, et al. Opioid antagonists for smoking cessation. Cochrane Database of Syst Rev. 2006;(4):CD003086.
16. Ray R, Jepson C, Patterson F, et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology. 2006;188:355-363. (Pubitemid 44387463)
17. Davis JA, Gould TJ. Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology. 2007;32:2011-2019. (Pubitemid 47258511)
18. Ray R, Rukstalis M, Jepson C, et al. Effects of Atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence. J Psychopharmacol. 2008; (Epub):1-9.
19. George TP, Vessicchio JC, Termine A, et al. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiat. 2003;53:136-143. (Pubitemid 36126476)
20. Ait-Daoud N, Lynch WJ, Penberthy JK, et al. Treating smoking dependence in depressed alcoholics. Alcohol Res Health. 2006;29:213-220.
21. Johnson BA, Ait-Daoud N, Akhtar FZ, et al. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial. Arch Intern Med. 2005;165:1600-1605. (Pubitemid 41124153)
22. Maurer P, Bachmann MF. Vaccination against nicotine: An emerging therapy for tobacco dependence. Expert Opin Inv Drug. 2007;16:1775-1783. (Pubitemid 350187391)
23. LeSage MG, Keyler DE, Hieda Y, et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology. 2006;184:409-416. (Pubitemid 43255857)
24. Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78:456-467. (Pubitemid 41698900)
25. Le Foll B, Goldberg SR. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport. 2004;15:2139-2143. (Pubitemid 39281762)
26. Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 2005;312:875-883. (Pubitemid 40293744)
27. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database of Syst Rev. 2007;(4):CD005353.
28. Andreoli M, Tessari M, Pilla M, et al. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotineseeking behavior. Neuropsychopharmacology. 2003;28:1272-1280. (Pubitemid 41070897)
29. Ross JT, Corrigall WA, Heidbreder CA., et al. Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive- ratio schedule in rats. Eur J Pharmacol. 2007;559:173-179. (Pubitemid 46295412)
30. Paterson NE, Semenova S, Gasparini F. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology. 2003;257-264 (Pubitemid 36712972)
31. Liechti ME, Lhuillier L, Kaupmann K, et al. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci. 2007;27:9077-9085. (Pubitemid 47312061)
32. Kenny PJ, Gasparini F, Markou A. Group II metabotropic and á-amino-3-hydroxy-5-methyl- 4-isoxazole propionate (AMPA)/Kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther. 2003;306:1068-1076. (Pubitemid 37025315)
33. Markou A. Metabotropic Glutamate Receptor Antagonists: Novel Therapeutics for Nicotine Dependence and Depression? Biol Psychiat. 2007; 61(1): 17-22. (Pubitemid 44855742)
34. Shiffman S, Fant RV, Buchhalter AR, et al. Nicotine delivery systems. Expert Opin Drug Delivery. 2005;2:563-577. (Pubitemid 41683228)
35. Metzger KL, Shoemaker JM, Kahn JB, et al. Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology. 2007;190:201-211. (Pubitemid 46011180)
36. Rabin C, Liang Y, Ehrlichman RS, et al. In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res. 2008;98:66-78. (Pubitemid 350235885)
37. Lerman CE, Schnoll RA, Munafo, MR. Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med. 2007;33:S398-405. (Pubitemid 350087622)
38. Munafo MR, Lerman C, Niaura R, et al. Smoking cessation treatment: Pharmacogenetic assessment. Curr Opin Mol Ther. 2005;7:202-208. (Pubitemid 40790542)
39. Caron L, Karkazis K, Raffin TA, et al. Nicotine addiction through a neurogenomic prism: Ethics, public health, and smoking. Nicotine Tob Res. 2005;7:181-197. (Pubitemid 40852145)
40. Shields A, Lerman C, Sullivan P. Translating emerging research on the genetics of smoking into clinical practice: Ethical and social con siderations. Nicotine Tob Res. 2004;6:675-688. (Pubitemid 39248154)
41. Ulh GR, Liu QR, Drgon T, et al. Molecular genetics of successful smoking cessation: Convergent genome-wide association results. Arch Gen Psychiat. 2008;65(6):683-693. (Pubitemid 351787239)
42. Murphy SA, Lynch KG, Oslin D, et al. Developing adaptive treatment strategies in substance abuse research. Drug Alcohol Depend. 2007;88S:S24-S30. (Pubitemid 46541624)